[1] Eugui EM,Almquist SJ,Muller CD.et al.Lymphocyte-selective cytostatic and immunosuppressive effects of mycophenolic acid in vitro: role of deoxyguanosine nucleotide depletion.Scand J Immunol,1991,33:161-173.
[2] Sollinger HW.Mycophenolate mofetil.Kidney Int Suppl,1995,52:S14-S17.
[3] Coma D,Morigi M,Facchinetti D,et al.Mycophenolate mofetil limits renal damage and prolongs life in murine lupus autoimmune disease.Kidney Int,1997.51:1583-1589.
[4] 胡伟新,黎磊石.重症狼疮性肾炎合并感染和肾衰应用霉酚酸酯治疗肾脏病与透析肾移植杂志,1997,6:491-497
[5] Hauser IA,Renders L.Radeke HH,et al.Mycophenolate mofetil inhibits rat and human mesangial cell proliferation by guanosine depletion.Nephrol Dial Transplant,1999,14:58 -63.
[6] 王金泉,刘志红,胡伟新,等.霉酚酸酯治疗难治性狼疮性肾炎肾组织病理的变化肾脏病与透析肾移植杂志,2000,9:18-22.
[7] Cohn RG,Mirkovich A,Dunlap B,et al.Mycophenolic acid increases apoptosis,lysosomes and lipid droplets in human lymphoid and monocytic cell lines.Transplantation,1999.68:411 -418.
[8] Nagy SE,Andersson JP,Andersson UG.Effect of mycophenolate mofetil (RS-61443)on cytokine production: inhibition of superantigen -induced cytokines.Immunopharmacology,1993,26:11-20.
[9] Jonsson CA,Svensson L,Carlsten H.Beneficial effect of the inosine monophosphate dehydrogenses inhibitor mycophenolate mofetil on survival and severity of glomerulonephritis in systemic lupus erythematosus(SLE)-prone MRL lpr/lpr mice.Clin Exp Inmunol,1999,116:534 -541.
[10] 胡伟新,刘志红,陈惠萍,等.霉酚酸酯治疗顽固性Ⅳ型狼疮性肾炎肾脏病与透析肾移植杂志,1998,7:511-515
[11] 胡伟新,陈惠萍,唐政,等.霉酚酸酯与间断环磷酰胺冲击疗法治疗Ⅳ型狼疮性肾炎疗效的比较肾脏病与透析肾移植杂志,2000,9:3-8.
[12] Haufs MG.Beissert S,Grabbe S.et al.Psoriasis vulgaris treated successfully with mvcophenolate mofetil.Br J Dermatol.1998,138:179-181.
[13] Shoji Y.Fukumura T,Kudo M.et al.Effect of topical preparation of mycophenolic acid on experimental allergic contact dermatitis of guinea-pigs induced bv dinitrofluorobenzene.J Pharm Pharmacol.1994,46:643-646.
[14] Bohm M.Beissert S.Schwatz T.et al.Bullous pemphigoid treated with mycophenolate mofetil.Lancet,1997.349(9051):541.
[15] Enk AH,Knop J.Treatment of pemphigus vulgaris with mycophenolate mofetil.Lancet,1997,350(9076):494.
[16] Grundmann-Kollmann M,Korting HC,Behrens S,et al.Mycophenolate mofetil: a new therapeutic option in the treattnent of blistering autoinmune diseases.J Am Acad Dermatol.1999,40:957 -960.
[17] Nousari HC,Sragovich A,Kimyai-Asadi A,et al.Mycophenolate mofetil in autoimmne and inflammatory skin disorders.J Am Acad Dermatol,1999,40:265-268.
[18] Nowack R,Birck R,van der Woude FJ.Mvcophenolate mofetil for svstetmic vasculitis and lgA nephropathy.Lancet.1997,349(9054):774.
[19] Nowack R,Gobel U,Klooker P,et al.Mycophenolate mofetil for maintenance therapy of Wegener's granulomatosis and microscopic polyangiitis: a pilot study in 11 patients with renal involvement.J Am Soc Nephrol,1999,10:1965-1971.
[20] Bullingham R.Monroe S.Nicholls A,et al.Pharmacokinetics and bioavailability of mvcophenolate mofetil in healthy subjects after single-dose oral and intravenous administration.J Clin Pharmacol.1996,36:315-324
[21] Kitchin JE,Pomeranz MK.Pak G.et al.Rediscovering myeophenolie acid: a review of its mechanism,side effects,and potential uses.J Am Acad Dermatoh 1997.37:445-449.
[22] Becker BN.Mycophenolate mofetil.Transplant Proc.1999.31:2777-2778. |
